EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines

Ana Peñata-Taborda iD, Pedro Espitia-Pérez iD, Lyda Espitia-Pérez iD, Andrés Coneo-Pretelt iD, Hugo Brango iD, Dina Ricardo-Caldera iD, Gean Arteaga-Arroyo iD, Luisa Jiménez-Vidal, Claudia Galeano-Páez iD, Karina Pastor-Sierra iD, Alicia Humanez-Alvarez iD, Osnamir Bru-Cordero iD und 4 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26031013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ana Peñata-Taborda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación Biomédicas y Biología Molecular, Universidad del Sinú E.B.Z., Montería 230001, Colombia. Hauptthemen laut MEDLINE: Isothiocyanates, Sulfoxides, Docetaxel, Mitochondria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MINCIENCIAS, Ministry of Science, Technology, and Innovation (MINCIENCIAS), Universidad del Sinú (UNISINU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Considering the limitations of monotherapies due to chemoresistance and side effects, this research aimed to determine whether low doses of sulforaphane (SFN) combined with docetaxel (DCT) could enhance therapeutic efficacy. Prostate cancer cell lines LNCaP and PC-3 were treated with individual IC50 doses of SFN and DCT and half-reduced IC50 values for the SFN:DCT combination. Metabolic markers, including glucose consumption, lactate production, reactive oxygen species (ROS), mitochondrial mass, and caspase activity, were assessed. In LNCaP cells, the SFN:DCT combination reduced cell viability to 50%, comparable to DCT monotherapy (48%). Caspase 3 activation was also higher with SFN:DCT (2.4 ± 0.75 RFU) than DCT alone (2.1 ± 0.47 RFU), while caspase 8 activation remained comparable, indicating equivalent effectiveness at lower concentrations. In PC-3 cells, the combination induced caspase 3 activation (1.16 ± 0.0484 RFU) at levels slightly lower than DCT (1.51 ± 0.2062 RFU) but achieved greater reductions in mitochondrial mass, reflecting its ability to target metabolic vulnerabilities in aggressive phenotypes. Our findings suggest that the SFN:DCT combination is a promising strategy for early-stage prostate cancer. By achieving comparable efficacy to DCT monotherapy at low doses, the SFN:DCT combination maintains the therapeutic impact, mitigating the adverse effects of conventional DCT treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsothiocyanatesSulfoxidesDocetaxelMitochondriaProstatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleCell Line, TumorReactive Oxygen SpeciesCell SurvivalApoptosisCaspase 3PC-3 CellsMetabolic Reprogramming

Stichwörter der Autor:innen

combination therapydocetaxelglycolysismitochondrial functionprostate cancerredox statussulforaphane

Substanzen

sulforaphaneIsothiocyanatesSulfoxidesDocetaxelReactive Oxygen SpeciesCaspase 3

Autor:innen und Institutionen

  • Grupo de Investigación Biomédicas y Biología Molecular, Universidad del Sinú E.B.Z., Montería 230001, Colombia.
  • Facultad de Educación y Ciencias, Departamento de Matemáticas, Universidad de Sucre, Sincelejo 700003, Colombia.
  • Grupo de Investigación Enfermedades Tropicales y Resistencia Bacteriana, Universidad del Sinú E.B.Z., Montería 230001, Colombia.
  • Dirección Académica, Universidad Nacional de Colombia, Kilómetro 9, Vía Valledupar-La Paz, La Paz 202010, Colombia.
  • Departamento de Ciencias Básicas, Escuela de Medicina, Universidad Industrial de Santander, Bucaramanga 680002, Colombia.
  • Escuela de Química, Universidad Industrial de Santander, Bucaramanga 680002, Colombia.

ORCID-Profile: Ana Peñata-Taborda, Pedro Espitia-Pérez, Lyda Espitia-Pérez, Andrés Coneo-Pretelt, Hugo Brango, Dina Ricardo-Caldera, Gean Arteaga-Arroyo, Claudia Galeano-Páez, Karina Pastor-Sierra, Alicia Humanez-Alvarez, Osnamir Bru-Cordero, Stelia Mendez-Sanchez, Mario Negrette-Guzmán

Förderung

  • MINCIENCIAS
  • Ministry of Science, Technology, and Innovation (MINCIENCIAS)
  • Universidad del Sinú (UNISINU)
  • Universidad Nacional de Colombia (UNAL)

Zitieren

APA

Peñata-Taborda, A., Espitia-Pérez, P., Espitia-Pérez, L., Coneo-Pretelt, A., Brango, H., Ricardo-Caldera, D., Arteaga-Arroyo, G., Jiménez-Vidal, L., Galeano-Páez, C., Pastor-Sierra, K., Humanez-Alvarez, A., Bru-Cordero, O., Jones-Cifuentes, N., Rincón-Orozco, B., Mendez-Sanchez, S., & Negrette-Guzmán, M. (2025). Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031013

Vancouver

Peñata-Taborda A, Espitia-Pérez P, Espitia-Pérez L, Coneo-Pretelt A, Brango H, Ricardo-Caldera D, et al. Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031013

BibTeX
@article{PeataTaborda2025,
  author = {Peñata-Taborda, Ana and Espitia-Pérez, Pedro and Espitia-Pérez, Lyda and Coneo-Pretelt, Andrés and Brango, Hugo and Ricardo-Caldera, Dina and Arteaga-Arroyo, Gean and Jiménez-Vidal, Luisa and Galeano-Páez, Claudia and Pastor-Sierra, Karina and Humanez-Alvarez, Alicia and Bru-Cordero, Osnamir and Jones-Cifuentes, Nathalia and Rincón-Orozco, Bladimiro and Mendez-Sanchez, Stelia and Negrette-Guzmán, Mario},
  title = {Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26031013}
}
Kostenlos starten →